Leiden and Utrecht, The Netherlands; 30 January 2017 – OcellO BV announced today that it has entered into a licensing agreement with Hubrecht Organoid Technology (HUB) for use of Organoid Technology for cystic fibrosis and gastrointestinal diseases, including colon cancer. OcellO will add these organoid assays to its drug discovery services portfolio.
Organoids are mini-organs grown in cell culture from biopsies taken from patients and faithfully recapitulate the genetic and phenotypic characteristics of diseased tissues. Organoids have proven to be valuable disease models for the high-throughput screening and validation of innovative medicines, bypassing limitations associated with cell-line- and xenograft-based preclinical drug studies.
Leo Price, CEO of OcellO, said: “HUB Organoid Technology represent the state-of-the-art for in vitro modelling of drug responses and is expected to form a spearhead in OcellO’s service offering. This licensing agreement is the culmination of a highly successful 3 year EU-funded collaboration (FP7-SUPPRESstem) to develop panels of organoid assays for colon cancer drug discovery and we are delighted to be able to offer these and other organoid assays to our customers.”
Marcel Zwaal, CEO of HUB: “We connect with companies that are able to offer high value added services to our Organoid Technology and with OcellO we have been fortunate to add an expert partner in this field”.
About the HUB
Hubrecht Organoid Technology (HUB) is an organization founded by the Royal Netherlands Academy of Sciences and the University Medical Center Utrecht. HUB exploits the pioneering work of Prof. Hans Clevers, who discovered methods to grow stem cell-derived human ‘mini-organs’ (HUB Organoids) from tissues of patients with various diseases. The organoids, that are part of the HUB biobanks, are characterized by genome sequencing, expression profiling and sensitivity to known and experimental drugs to establish a database linking genetic and transcriptional information to drug responsiveness. HUB offers licenses to its patented HUB Organoid Technology for drug-screening and access to organoids in the HUB biobanks for preclinical drug discovery and validation. In addition, HUB is performing clinical studies to validate the technologies use as a companion diagnostic. More info at www.hub4organoids.eu
OcellO is a CRO that offers drug screening and profiling services using 3D cell culture models of disease. OcellO uses high-content 3D imaging and analysis to measure drug effects, extracting clinically relevant information on compound effects. OcellO has developed a broad range of models for testing potential therapies to treat polycystic kidney disease, neurodegenerative disorders and, in particular, cancer. OcellO’s current 3D cancer models are developed from cell lines, patient derived xenograft tumours and patient tumour material, and include panels of lung, pancreas, breast, colon and gastric cancers.
Leo Price (CEO)
Phone: +31 71 3322 875
Robert Vries (COO)
Tel: +31 88 1236 301